Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HS-10241 +/- Apatinib in Advanced Solid Tumors
NCT03243643Phase 1Unknown
- Sponsor
- Hansoh Pharmaceutical Group
- Start
- Aug 2017
- Primary completion
- Jul 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of dalmelitinib in solid tumor (advanced stage) and non-small cell lung cancer (NSCLC), sponsored by Hansoh Pharmaceutical Group. Primary endpoints: Dose Limiting Toxicities and Maximum Tolerated Dose. Status: unknown.
02
Drugs
dalmelitinib
03
Conditions
solid tumor (advanced stage)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03243643.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03243643.